Document is current
Any future updates will be listed below
-
Authors
Hsieh, Marvin L
Nishizaki, Daisuke
Adashek, Jacob J
Kato, Shumei
Kurzrock, Razelle
-
Funding
Funding for this research was provided by:
National Institutes of Health (5UG1CA233198-05)
- License Information
-
More Information
Article History
Received: 8 November 2024
Accepted: 2 February 2025
First Online: 23 February 2025
Declarations
:
: Not applicable.
: Not applicable.
: JA serves on the advisory board of CureMatch and is a consultant for datma. SK serves as a consultant for Medpace, Foundation Medicine, NeoGenomics, and CureMatch. He receives speaker’s fees from Roche and Bayer, and the advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta, OmniSeq, and Personalis. RK has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Sysmex, Takeda, and TopAlliance and from the NCI; as well as consultant and/or speaker fees and/or advisory board/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Precirix, Prosperdtx, Recordati, Regeneron, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc.; serves on the Board of CureMatch and CureMetrix and XZOM, and is a co-founder of CureMatch.
